Many cancer survivors report cognitive changes — trouble with thinking, memory, and concentration — related to cancer and cancer treatments, particularly chemotherapy. Sometimes referred to as “chemobrain” or “chemofog,” the phenomenon formally referred to as cancer-related cognitive impairment has been an important concern for clinical practitioners and investigators. Overall, research findings have demonstrated changes in several domains of cognition, including working memory, new learning, executive function, and spatial abilities. However, questions remain in the areas of how to measure these changes, how to interpret findings across research studies, and whether neuropsychological test results can be generalized to everyday tasks. Moreover, not all cancer patients and survivors experience cognitive late effects, and determining susceptibility and identifying neural pathways remain important areas of exploration. Also, there are limited validated interventions available for patients suffering from these symptoms, and further work is needed to provide practitioners and patients with advice about accommodation strategies and empirically sound therapies.
The BBPSB focus expands across the cancer control continuum, examining cognition from pre-treatment through end of life, including in long-term survivors. The branch is interested in the problem of cancer-related cognitive changes from the perspectives of cognitive, clinical, and neurodevelopmental psychology and of neuroscience.
Articles and Publications
Preventing Chemo Brain? Study Identifies Potential Approach for Common Problem. NCI Staff. Cancer Currents blog, National Cancer Institute, 2022.
Physical Activity May Lessen the Effects of Chemobrain, Study Finds. NCI Staff. Cancer Currents blog, National Cancer Institute, 2021.
Treviño M, Zhu X, Lu YY, Scheuer LS, Passell E, Huang GC, Germine LT, Horowitz TS. How do we measure attention? Using factor analysis to establish construct validity of neuropsychological tests. Cogn Res Princ Implic. 2021 Jul 22;6(1):51. doi: 10.1186/s41235-021-00313-1.
Horowitz TS, Trevino M, Gooch IM, Duffy KA. Understanding the Profile of Cancer-Related Cognitive Impairments: A Critique of the Meta-Analyses. J Natl Cancer Inst. 2019 May. doi: 10.1093/jnci/djz100.
Horowitz T. What You Need to Know About Cancer-Related Cognitive Impairment.
Horowitz T, Suls J, Trevino M. A call for a neuroscience approach to cancer-related cognitive impairment. Trends Neurosci. 2018 Aug;41(8):493-496. doi: 10.1016/j.tins.2018.05.001. Epub 2018 Jun 12.
Understanding “Chemobrain” and Cognitive Impairment after Cancer Treatment. National Cancer Institute (2017).
Funding Opportunities
| Title | Announcement # | Expiration Date | Contact |
| Research Project Grant | PA-20-185 (Parent R01 Clinical Trial Not Allowed)
PA-20-184 (Parent R01 Basic Experimental Studies with Humans Required) PA-20-183 (Parent R01 Clinical Trial Required) |
May 08, 2024 | Research Program Contacts |
| Cancer Prevention and Control Clinical Trials Grant Program | PAR-21-035 (R01 Clinical Trial Required) | January 08, 2024 | Susan Czajkowski
240-276-5871 Susan.Czajkowski@nih.gov |
| Modular R01s in Cancer Control and Population Sciences | PAR-21-190 (R01 Clinical Trial Optional) | March 08, 2024 | Scott Rogers
240-276-6932 rogerssc@mail.nih.gov |
| Exploratory Grants in Cancer Control | PAR-21-341 (R21 Clinical Trial Optional) | October 09, 2024 | Mukesh Verma
240-276-6889 vermam@mail.nih.gov Tanya Agurs-Collins 240-276-6956 collinsta@mail.nih.gov |
| Notice of NIH Participation in the National Science Foundation Solicitation NSF 23-614: Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science
More Information |
NOT-OD-23-165 | November 09, 2023 | Dana Wolff-Hughes
240-620-0673 dana.wolff@nih.gov |
Contact
